Overview
Genoox provides a cloud-based platform that turns raw genomic data into clinical results for hospitals, research institutions, and clinical laboratories. It manages the sequencing workflow from data ingestion to actionable insights, offering tools for variant calling, annotation, and automated genotype-phenotype correlation, along with storage and data processing features all accessible via a subscription. The platform is designed to support end-to-end genomic data analysis in a single environment, complemented by professional services and support. What makes Genoox different is its integrated end-to-end workflow on one cloud platform, including an annotation engine and automated genotype-phenotype links, plus a 14-day free trial to attract users. The company's goal is to help healthcare professionals and researchers efficiently convert genomic data into clinically meaningful information and insights.
Work here?Claim your company
Simplify's take
What believers are saying
- HGMD became available in Franklin on November 9, 2026, widening interpretive depth.
- QIAGEN says Franklin supports over 750,000 case interpretations, proving real workflow adoption.
- Thermo Fisher collaboration and MGI partnership extend channel reach across labs.
What critics are saying
- QIAGEN acquired Genoox in May 2025 for $70 million, ending startup independence.
- Franklin is labeled research-only in June 2026, limiting clinical decision-making claims.
- QIAGEN can fold Franklin into QDI, freezing Genoox brand and standalone roadmap.
What makes Genoox unique
- Franklin by QIAGEN combines AI variant prioritization, somatic interpretation, and HGMD content.
- It serves 4,000 healthcare organizations across 50 countries, spanning germline and somatic analysis.
- QIAGEN integration adds COSMIC, QKB, and global commercial distribution.
Help us improve and share your feedback! Did you find this helpful?